DK0972032T3 - Peptider til behandling af systemisk lupus erythematosus - Google Patents
Peptider til behandling af systemisk lupus erythematosusInfo
- Publication number
- DK0972032T3 DK0972032T3 DK98907114T DK98907114T DK0972032T3 DK 0972032 T3 DK0972032 T3 DK 0972032T3 DK 98907114 T DK98907114 T DK 98907114T DK 98907114 T DK98907114 T DK 98907114T DK 0972032 T3 DK0972032 T3 DK 0972032T3
- Authority
- DK
- Denmark
- Prior art keywords
- lupus erythematosus
- systemic lupus
- peptides
- treatment
- laminin
- Prior art date
Links
- 201000000596 systemic lupus erythematosus Diseases 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- YIYCUMYWGOOSNU-FMZZOXHWSA-N 2-[[(2s)-1-[(2s,3s)-2-[[(2s,3r)-2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O YIYCUMYWGOOSNU-FMZZOXHWSA-N 0.000 abstract 2
- 102000007547 Laminin Human genes 0.000 abstract 1
- 108010085895 Laminin Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000010352 biotechnological method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12050397A IL120503A0 (en) | 1997-03-20 | 1997-03-20 | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them |
| PCT/IB1998/000415 WO1998042737A2 (en) | 1997-03-20 | 1998-03-20 | Peptides for the treatment of systemic lupus erythematosus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0972032T3 true DK0972032T3 (da) | 2007-04-10 |
Family
ID=11069947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98907114T DK0972032T3 (da) | 1997-03-20 | 1998-03-20 | Peptider til behandling af systemisk lupus erythematosus |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6228363B1 (da) |
| EP (1) | EP0972032B1 (da) |
| JP (1) | JP4459307B2 (da) |
| AT (1) | ATE348885T1 (da) |
| AU (1) | AU734444B2 (da) |
| CA (1) | CA2283792A1 (da) |
| DE (1) | DE69836679T2 (da) |
| DK (1) | DK0972032T3 (da) |
| ES (1) | ES2279567T3 (da) |
| IL (2) | IL120503A0 (da) |
| NZ (1) | NZ337953A (da) |
| PT (1) | PT972032E (da) |
| WO (1) | WO1998042737A2 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001005812A2 (en) * | 1999-07-15 | 2001-01-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | PEPTIDES AND THEIR UTILITY IN MODULATION OF BEHAVIOR OF CELLS EXPRESSING α3β1 INTEGRINS |
| US7129052B1 (en) | 2000-07-12 | 2006-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins |
| WO2001061349A1 (en) * | 2000-02-18 | 2001-08-23 | The University Of Tennessee Research Corporation | Detection of microbial deposition and immune response at the basement membrane |
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| JP2006516034A (ja) * | 2003-01-14 | 2006-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | 全身性エリテマトーデスを治療するためのペプチドの非経口製剤 |
| KR20050100617A (ko) * | 2003-01-14 | 2005-10-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 전신 홍반 루푸스 치료용 펩티드의 비 경구 제형 |
| CA2605321A1 (en) | 2005-04-19 | 2006-10-26 | Eli Lilly And Company | Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease |
| CN101720231A (zh) * | 2007-05-24 | 2010-06-02 | 哈德西特有限公司 | 治疗全身性红斑狼疮的肽和治疗全身性红斑狼疮的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266328A (en) * | 1990-08-27 | 1993-11-30 | Regents Of The University Of Minnesota | Laminin a chain polypeptides from the carboxy terminal globular domain |
| WO1992004914A1 (en) | 1990-09-14 | 1992-04-02 | The Trustees Of The University Of Pennsylvania | Design of bioactive peptides based on immunoglobulin structure |
| US6013628A (en) * | 1994-02-28 | 2000-01-11 | Regents Of The University Of Minnesota | Method for treating conditions of the eye using polypeptides |
| IL108811A (en) * | 1994-03-01 | 1998-06-15 | Hadasit Med Res Service | Immunoassay reagents, kits and methods |
| US5493008A (en) * | 1994-08-15 | 1996-02-20 | The University Of Virginia Patent Foundation | Two non-contiguous regions contribute to nidogen binding to a single EGF-like motif of the laminin γ1 chain |
| EP0765660A3 (en) * | 1995-09-28 | 1998-09-23 | Takeda Chemical Industries, Ltd. | Microcapsules comprising 2-piperazinone-1-acetic acid compounds |
-
1997
- 1997-03-20 IL IL12050397A patent/IL120503A0/xx unknown
-
1998
- 1998-03-20 ES ES98907114T patent/ES2279567T3/es not_active Expired - Lifetime
- 1998-03-20 AU AU63065/98A patent/AU734444B2/en not_active Ceased
- 1998-03-20 WO PCT/IB1998/000415 patent/WO1998042737A2/en not_active Ceased
- 1998-03-20 EP EP98907114A patent/EP0972032B1/en not_active Expired - Lifetime
- 1998-03-20 AT AT98907114T patent/ATE348885T1/de not_active IP Right Cessation
- 1998-03-20 DE DE69836679T patent/DE69836679T2/de not_active Expired - Lifetime
- 1998-03-20 NZ NZ337953A patent/NZ337953A/en unknown
- 1998-03-20 JP JP54532898A patent/JP4459307B2/ja not_active Expired - Fee Related
- 1998-03-20 CA CA002283792A patent/CA2283792A1/en not_active Abandoned
- 1998-03-20 DK DK98907114T patent/DK0972032T3/da active
- 1998-03-20 PT PT98907114T patent/PT972032E/pt unknown
-
1999
- 1999-09-16 IL IL131950A patent/IL131950A/en not_active IP Right Cessation
- 1999-09-20 US US09/399,494 patent/US6228363B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69836679T2 (de) | 2007-10-04 |
| JP2001524826A (ja) | 2001-12-04 |
| EP0972032B1 (en) | 2006-12-20 |
| WO1998042737A3 (en) | 1998-11-05 |
| US6228363B1 (en) | 2001-05-08 |
| JP4459307B2 (ja) | 2010-04-28 |
| NZ337953A (en) | 2002-03-28 |
| IL131950A (en) | 2006-07-05 |
| WO1998042737A2 (en) | 1998-10-01 |
| IL120503A0 (en) | 1997-07-13 |
| CA2283792A1 (en) | 1998-10-01 |
| DE69836679D1 (de) | 2007-02-01 |
| PT972032E (pt) | 2007-03-30 |
| AU6306598A (en) | 1998-10-20 |
| AU734444B2 (en) | 2001-06-14 |
| EP0972032A2 (en) | 2000-01-19 |
| ES2279567T3 (es) | 2007-08-16 |
| ATE348885T1 (de) | 2007-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69533855D1 (de) | UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG | |
| NO165547C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive androsta-1,4-dien-3,17-dioner. | |
| DE59705683D1 (de) | IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG | |
| DE69823459D1 (de) | Herzbehandlungssystem zur Feststellung und Behandlung von Herzversagen | |
| ATE214924T1 (de) | Verwendung von nebivolol als anti-atherogenisches mittel | |
| ATE308327T1 (de) | Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs | |
| ATE242005T1 (de) | P277 peptidanaloge, pharmazeutische zusammenstellung davon zur behandlung und diagnose von diabetes | |
| DK0972032T3 (da) | Peptider til behandling af systemisk lupus erythematosus | |
| DE69329656D1 (de) | Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen | |
| DE69625682D1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
| BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
| EP0783524A4 (en) | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| ES2130629T3 (es) | Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i. | |
| WO2008142694A3 (en) | Peptides and methods for the treatment of systemic lupus erythematosus | |
| DE69738600D1 (de) | Neuroaktive peptide | |
| ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
| DE69326145D1 (de) | Synthetische peptide für die behandlung von myasthenia gravis | |
| TR200100175T2 (tr) | Otoimmün hastalıkların immünoterapisinde kullanılmak üzere yeni peptitler. | |
| NO963347L (no) | Fremgangsmåte for identifisering av individer som lider av en cellulær abnormitet | |
| ATE260111T1 (de) | Mittel zur behandlung von autoimmunkrankheiten | |
| TR200003352T2 (tr) | Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler | |
| FI973762A0 (fi) | Ny gen | |
| AU2791295A (en) | Method of determining the amount of active substance released from solid or semi-solid preparations administered to humans or animals | |
| IL114460A0 (en) | Peptide p277 analogs and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes | |
| DE59609353D1 (de) | Mittel zur subkutanen Verabreichung von Protein C |